Results 241 to 250 of about 164,986 (311)

Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To understand real‐world tirzepatide use among individuals without type 2 diabetes (T2D) diagnoses in a US electronic health record (EHR) database. Materials and Methods This retrospective, descriptive, cohort study used Veradigm's® Network EHR database linked with administrative claims.
Theresa Hunter Gibble   +7 more
wiley   +1 more source

Evaluation of sleep position shifts in patients with obstructive sleep apnea syndrome with the use of a mandibular advancement device. [PDF]

open access: yesFront Dent Med
Ciavarella D   +9 more
europepmc   +1 more source

Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess real‐world use of Saxenda® (liraglutide 3.0 mg) and off‐label use of Victoza® (liraglutide 1.2 mg/1.8 mg) for weight management and Saxenda® posology in the United Kingdom. Their similar doses and formulation pose a risk of inadvertent use due to their use for different indications.
Tarita Murray‐Thomas   +5 more
wiley   +1 more source

The prevalence and predictors of obstructive sleep apnea in patients undergoing bariatric surgery in Saudi Arabia. [PDF]

open access: yesSaudi Med J
Alaqeel AM   +8 more
europepmc   +1 more source

Circadian misalignment disrupts biomarkers of cardiovascular disease risk and promotes a hypercoagulable state

open access: yesEuropean Journal of Neuroscience, Volume 60, Issue 7, Page 5450-5466, October 2024.
We studied the impact of circadian misalignment on 238 plasma proteins linked to cardiovascular physiology. We identified 42 proteins with altered abundance, five proteins regulated by the circadian clock, and changes in many proteins in the coagulation pathway.
Andrew W. McHill   +3 more
wiley   +1 more source

Brain 18F‐fluorodeoxyglucose positron emission tomography: An efficient tool at the initial diagnosis of nonlesional late onset epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective This study evaluates the diagnostic performance and prognostic value of brain 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography (PET) at the initial diagnosis of patients with nonlesional late onset epilepsy (NLLOE). Methods In this cohort study at the University Hospital of Nancy, France, newly diagnosed NLLOE patients, >
Salomé Puisieux   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy